XSHE300653
Market cap486mUSD
Jan 10, Last price
19.89CNY
1D
-1.68%
1Q
-12.11%
IPO
140.99%
Name
Yantai Zhenghai Bio-Tech Co Ltd
Chart & Performance
Profile
Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and marketing of regenerative medical materials in China. It offers bone repair material, a partially deproteinised bone prepared from cancellous bones of calves after a series of treatment, such as decellularization and degreasing; oral cavity repair membrane line of products, which are used to treat defects of shallow oral cavity's soft tissue; and bio-membrane line of products that are used in neurosurgery to repair cerebral dura mater defect under the Heal-All brand name. The company also provides skin repair membrane line of products to repair wounds in dermal layer under the Heal-Full brand name. Yantai Zhenghai Biotechnology Co., Ltd. was founded in 2003 and is based in Yantai, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 413,653 -4.52% | 433,225 8.26% | |||||||
Cost of revenue | 170,932 | 211,749 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 242,721 | 221,476 | |||||||
NOPBT Margin | 58.68% | 51.12% | |||||||
Operating Taxes | 27,438 | 26,671 | |||||||
Tax Rate | 11.30% | 12.04% | |||||||
NOPAT | 215,283 | 194,804 | |||||||
Net income | 190,958 2.98% | 185,437 10.02% | |||||||
Dividends | (108,000) | (105,600) | |||||||
Dividend yield | 2.07% | 1.70% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 25,150 | ||||||||
Long-term debt | |||||||||
Deferred revenue | 9,124 | 9,961 | |||||||
Other long-term liabilities | |||||||||
Net debt | (675,276) | (592,360) | |||||||
Cash flow | |||||||||
Cash from operating activities | 180,478 | 187,838 | |||||||
CAPEX | (31,877) | ||||||||
Cash from investing activities | (86,130) | ||||||||
Cash from financing activities | (108,005) | ||||||||
FCF | 200,883 | 173,718 | |||||||
Balance | |||||||||
Cash | 675,188 | 616,702 | |||||||
Long term investments | 89 | 808 | |||||||
Excess cash | 654,594 | 595,849 | |||||||
Stockholders' equity | 679,445 | 695,690 | |||||||
Invested Capital | 302,596 | 294,749 | |||||||
ROIC | 72.08% | 71.09% | |||||||
ROCE | 25.18% | 24.70% | |||||||
EV | |||||||||
Common stock shares outstanding | 180,149 | 144,873 | |||||||
Price | 29.02 -32.51% | 43.00 -3.40% | |||||||
Market cap | 5,227,914 -16.08% | 6,229,518 -21.95% | |||||||
EV | 4,552,638 | 5,637,157 | |||||||
EBITDA | 263,237 | 240,580 | |||||||
EV/EBITDA | 17.29 | 23.43 | |||||||
Interest | |||||||||
Interest/NOPBT |